Search
Paliperidone
go.drugbank.com/drugs/DB01267ApprovedInvestigationalPaliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. … Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug.
Zalcitabine
go.drugbank.com/drugs/DB00943ApprovedWithdrawnThe compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. … Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseSynonyms: 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-oneTrastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigationalWhile Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, it is the second biosimilar approved in the U.S. for the treatment of cancer. … [L14015] It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER
Categories: Complex MixturesCrotalus scutulatus antivenin
go.drugbank.com/drugs/DB13891ApprovedCrotalus scutulatus antivenin is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus scutulatus (also known as the _Mojave … CroFab is more specifically tailored for crotalids of North America and is less allergenic than whole immunoglobulin antivenoms [L2861].
Factor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalCompared to Factor XIII (human), which is purified from pooled human plasma, [DB09310] is produced through recombinant DNA technology where the target protein is grown in yeast and then isolated [FDA Label … Also known as Fibrin Stabilizing Factor (FSF), Factor XIII is an endogenously produced coagulation factor and the final enzyme within the blood coagulation cascade.
Cefprozil
go.drugbank.com/drugs/DB01150ApprovedInvestigationalCefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [A261130] Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa).
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalDeucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered
Natalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigationalNatalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin.
Benralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigational[A31294] It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction. … It is an afucosylated IgG which gives it high affinity for the FcγRIIIα receptor in natural killer cells, macrophages and neutrophils.